Poolbeg Pharma, founded by Cathal Friel, operates with a distinct approach to funding and development. Friel, a renowned financier, has a track record of successfully launching and selling companies through Raglan Capital, his private equity vehicle. Over the past decade, Raglan Capital has facilitated five initial public offerings, each following a strategic blueprint.
The Raglan method begins by attracting private investors to finance the revival of undervalued yet promising assets, often referred to as orphans. Once rehabilitated, these assets are floated, allowing access to public market capital for strategic acquisitions. This process culminates in a substantial sale, providing a lucrative exit for the original investors, and setting the stage for the cycle to repeat.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
